NELSEN ROBERT 1219042 Data last updated 2024-05-11 06:58:14 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-24 | 2023-05-22 | 2023-05-22 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 6027.0 | 1.05 | 0.45 | 0.0 | Direct | Common Stock | VIR BIOTECHNOLOGY, INC. | code A | 576148.0 | 133.98 (VIR) |
| 2023-05-24 | 2023-05-22 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 5626008.0 | 0 | 419.92 | 0.0 | Arch Venture Fund Ix | Common Stock | VIR BIOTECHNOLOGY, INC. | NA | 133.98 (VIR) | ||
| 2023-05-24 | 2023-05-22 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 7290655.0 | 0 | 544.17 | 0.0 | Arch Venture Fund Ix Overage | Common Stock | VIR BIOTECHNOLOGY, INC. | NA | 133.98 (VIR) | ||
| 2023-05-24 | 2023-05-22 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 33893.0 | 0 | 2.53 | 0.0 | A Trust For The Benefit Of Family Members Of The Reporting Person | Common Stock | VIR BIOTECHNOLOGY, INC. | NA | 133.98 (VIR) | ||
| 2023-09-08 | 2023-09-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 18206358.0 | 0 | 725.27 | 0.0 | Arch Venture Fund Ix Overage, L.P. | Common Stock | LYELL IMMUNOPHARMA, INC. | NA | 251.03 (LYEL) | ||
| 2023-09-08 | 2023-09-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 18206358.0 | 0 | 725.27 | 0.0 | Arch Venture Fund Ix, L.P. | Common Stock | LYELL IMMUNOPHARMA, INC. | NA | 251.03 (LYEL) | ||
| 2023-06-20 | 2023-06-16 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 18206358.0 | 0 | 729.39 | 0.0 | Arch Venture Fund Ix Overage, L.P. | Common Stock | LYELL IMMUNOPHARMA, INC. | NA | 249.61 (LYEL) | ||
| 2023-06-20 | 2023-06-16 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 18206358.0 | 0 | 729.39 | 0.0 | Arch Venture Fund Ix, L.P. | Common Stock | LYELL IMMUNOPHARMA, INC. | NA | 249.61 (LYEL) | ||
| 2024-02-12 | 2024-02-08 | 2024-02-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 727272.0 | 5.84 | 36.89 | 5.5 | See Footnote F5 | Common Stock | SANA BIOTECHNOLOGY, INC. | code P | 12446022.0 | 197.13 (SANA) |
| 2024-02-12 | 2024-02-08 | 2024-02-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 727272.0 | 5.84 | 36.89 | 5.5 | See Footnote F4 | Common Stock | SANA BIOTECHNOLOGY, INC. | code P | 12446022.0 | 197.13 (SANA) |
| 2024-02-12 | 2024-02-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 10301250.0 | 0 | 522.55 | 0.0 | See Footnote F2 | Common Stock | SANA BIOTECHNOLOGY, INC. | NA | 197.13 (SANA) | ||
| 2024-02-12 | 2024-02-08 | 2024-02-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 363637.0 | 3.41 | 18.45 | 5.5 | See Footnote F1 | Common Stock | SANA BIOTECHNOLOGY, INC. | code P | 10667387.0 | 197.13 (SANA) |
| 2024-02-12 | 2024-02-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 12500.0 | 0 | 0.63 | 0.0 | Enzo Family Trust Of 2015 | Common Stock | SANA BIOTECHNOLOGY, INC. | NA | 197.13 (SANA) | ||
| 2024-02-12 | 2024-02-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 1353.0 | 0 | 0.07 | 0.0 | Direct | Common Stock | SANA BIOTECHNOLOGY, INC. | NA | 197.13 (SANA) | ||
| 2024-02-20 | 2024-02-15 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 6128297.0 | 0 | 629.68 | 0.0 | By Arch Venture Fund X Overage, L.P. | Common Stock | PRIME MEDICINE, INC. | NA | 97.32 (PRME) | ||
| 2024-02-20 | 2024-02-15 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 6128297.0 | 0 | 629.68 | 0.0 | By Arch Venture Fund X, L.P. | Common Stock | PRIME MEDICINE, INC. | NA | 97.32 (PRME) | ||
| 2024-02-20 | 2024-02-15 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | holding | 16080.0 | 0 | 1.65 | 0.0 | A Trust For The Benefit Of Family Members Of The Reporting Person | Common Stock | PRIME MEDICINE, INC. | NA | 97.32 (PRME) | ||
| 2024-02-20 | 2024-02-15 | 2024-02-15 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 3200000.0 | 100.0 | 328.8 | 6.25 | By Arch Venture Fund Xii, L.P. | Common Stock | PRIME MEDICINE, INC. | code P | 3200000.0 | 97.32 (PRME) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-24 | 2023-05-22 | 2023-05-22 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 12054.0 | 100.0 | 0.9 | 25.74 | Direct | Stock Option (Right To Buy) | VIR BIOTECHNOLOGY, INC. | code A | 12054.0 | 133.98 (VIR) |
| 2023-06-12 | 2023-06-08 | 2023-06-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 65000.0 | 100.0 | 3.39 | 6.7 | Direct | Stock Option (Right To Buy) | SANA BIOTECHNOLOGY, INC. | code A | 65000.0 | 191.5 (SANA) |
| 2023-06-16 | 2023-06-14 | 2023-06-14 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 39062.0 | 100.0 | 4.02 | 14.83 | Direct | Stock Option (Right To Buy) | PRIME MEDICINE, INC. | code A | 39062.0 | 97.23 (PRME) |
| 2023-09-08 | 2023-09-08 | 2023-09-08 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 55000.0 | 100.0 | 2.19 | 3.19 | Direct | Option (Right To Buy) | LYELL IMMUNOPHARMA, INC. | code A | 55000.0 | 251.03 (LYEL) |
| 2023-06-20 | 2023-06-16 | 2023-06-16 | 4 | Nelsen Robert | DIRECTOR, 10% OWNER | acq | 65000.0 | 100.0 | 2.6 | 3.19 | Direct | Option (Right To Buy) | LYELL IMMUNOPHARMA, INC. | code A | 65000.0 | 249.61 (LYEL) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)